Symbol search
date o news sym
marketwatch
11:10 Tue 4
OthrMvrs
Rapid COVID test maker Precipio soars in premarket trade
-
http://feeds.marketwatch.com/~r/marketwatch/bulletins/~3/K-WSg91cGXI/go
PRPO
Healt
Text search
date o news
marketwatch
11:10 Tue 4
OthrMvrs
Rapid COVID test maker Precipio soars in premarket trade
-
PRPO
Healt
marketwatch
11:42 Tue 4
UPDATE: Precipio shares soar 32% premarket after rapid COVID test becomes available on Amazon
Shares of microcap Precipio Inc. , a specialty diagnostics company, soared 32% in premarket trade Tuesday, adding to gains of more than 170% on Monday, after the company said its COVID-19 rapid antibody test is now available on Amazon.com's business platform. The 20-minute test, which was awarded emergency use authorization from the U.S. Food and Drug Administration in December, can only be purchased by qualified medical point-of-care providers. 'Physicians and other medical facilities may now purchase these items directly from Amazon, and receive them within 2 business days,' the company said in a statement on Monday. The test can identify the presence of antibodies that have been developed from exposure to the coronavirus-borne illness, or from vaccination and show an immune response. 'Antibodies are the body's natural biological response to an infection or vaccination, and their development begins the body's process of building immunity to protect against future infections,' Precipio said in the statement. The stock has gained 139% in the year to date, while the S&P 500 has gained 11.6%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
PRPO
Healt
@MarketCurrents
13:58 Mon 3
OthrMvrs
$PRPO $PRPO $AMZN - Precipio shares jump on launching its rapid COVID-19 antibody test on Amazon platform https://t.co/lEbNWDWofP
-
PRPO
Healt
marketwatch
1h ago
TrdId
Vaccine makers lower after U.S. says it supports IP waivers
Vaccine makers Pfizer , BioNTech and Moderna each traded lower by 3% to 5% in premarket trade on Thursday, following the announcement from U.S. Trade Representative Katherine Tai that the U.S. supports the waiver of intellectual-property protections on COVID-19 vaccines. Another maker of COVID-19 vaccines, AstraZeneca , was flat in London trade. Moderna also is scheduled to report earnings on Thursday. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.


globenewswire
13:30 Mon 3
Nws
Precipio Launches its Rapid COVID-19 Antibody test on Amazon Platform
Nirmidas test is available to POC healthcare providers with an Amazon business account Nirmidas test is available to POC healthcare providers with an Amazon business account
PRPO
Healt
prnewswire:443
17:34 Wed 5
Nws
Kroger Health Launches Over-the-Counter Rapid Antigen Self-Test Kits
CINCINNATI, May 5, 2021 /PRNewswire/ -- Kroger Health, the healthcare division of The Kroger Co. (NYSE: KR), today announced the launch of Abbott's BinaxNOW COVID-19 Antigen Self Test, an over-the-counter SARS-CoV-2 rapid antigen test that has received FDA Emergency Use Authorization for...
KR
Consu
forbes
19:30 Tue 4
Mrkts
New Data Shows 2021 U.S. Trade Soars Past Pre-Covid 2019 Record Total
U.S. trade totaled $1.40 trillion in the first quarter, according to government data released Tuesday.


proactiveinvestors
12:01 Tue 4
Wall Street set for a mixed start
The main Wall Street indices are expected to open mostly lower on Tuesday except for the narrowly-based Dow Jones 30-share index. The Dow Jones Industrial Average is tipped to edge 19 points higher to 23,132 but the more broadly-based S&P 500 is seen giving up 4 points at 4,189 while the tech-heavy Nasdaq 100 is expected to slide 20 points to 13,759. Drugs giant Pfizer Inc (NYSE:PFE), which unlike its Anglo-Swedish counterpart AstraZeneca PLC (LON:AZN) is not providing its COVID vaccine at cost, has lifted earnings guidance on the back of better-than-expected take-up of its vaccine. DuPont de Nemours Inc (NYSE:DD), the speciality materials, chemicals and agricultural products conglomerate, also lifted its full-year outlook after its first-quarter sales and earnings beat the markets expectations. Today will see the release of US factory orders and the US trade balance. Factory orders for March are expected to have risen 1.3% in March after falling 0.8%, while the trade deficit is expected to widen to US$74.3bn from Februarys US$71.1bn. Four things to watch for on Tuesday: Earnings reports are due today from a number of major firms including telecoms giant T-Mobile US Inc (NASDAQ:TMUS), video game publisher Activision Blizzard Inc (NASDAQ:ATVI) and oil & gas explorer ConocoPhillips (NYSE:COP) Shares in diagnostics firm Precipio Inc (NASDAQ:PRPO) are also in focus after the firm launched its rapid COVID-19 antibody test on Amazon overnight Pharmacy chain CVS Health Corp (NYSE:CVS) may get a look in after it upgraded its outlook and beat expectations with its latest earnings Crypto markets may also come to the fore after meme-inspired crypto Dogecoin surged in value following its listing on trading platform eToro


marketwatch
11:06 Tue 4
Nws
Arconic shares jump 2% premarket as earnings beat, company raises guidance
Arconic Inc. shares rose 2% in premarket trade Tuesday, after the company posted better-than-expected first-quarter earnings and raised guidance, citing higher aluminum prices and strong orders from the aerospace sector. The maker of aluminum panels for cars and planes said it had net income of $52 million, or 46 cents a share, in the quarter, up from $46 million, or 42 cents a share, in the year-earlier period. Sales rose to $1.675 billion from $1.611 billion a year ago. The FactSet consensus was for EPS of 30 cents and sales of $1.535 billion. 'We captured growth in international packaging due to better than expected regional strength and industrial end markets improved as the trade litigation came to a final positive ruling at the end of March,' Chief Executive Tim Myers said in a statement. 'Ground transportation sales also grew, largely driven by commercial transportation, but were constrained by weather impacts and the semiconductor shortage.' Arconic secured long-term contracts equal to more than $2 billion in aerospace revenue and negotiated agreements for about $1.5 billion in North American packaging revenue from 2022 to 2024, he said. It also completed a $1 billion U.S. pension partial annuitization and authorized a share buyback program of up to $300 million. The company also raised its guidance and now expects full-year revenue to range from $7.1 billion to $7.4 billion, up from prior guidance of $6.6 billion to $6.9 billion. The FactSet consensus is for sales of $6.6 billion. Shares have fallen 1.5% in the year to date, while the S&P 500 has gained 11.6%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
ARNC
Indus
proactiveinvestors
13:38 Tue 4
Wall Street opens in the red as momentum slows
The main indices on Wall Street started Tuesdays session on a lower footing as investors in New York appeared to be running out of steam. Shortly after the opening bell, the Dow Jones Industrial Average was down 0.22% at 34,038 while the S&P 500 dropped 0.54% to 4,170 and the Nasdaq fell 1.1% to 13,741. Seeing better luck was pharmaceuticals giant Pfizer Inc, which was up 0.3% at US$39.93 in early deals after it upgraded forecasts in its quarterly results. 8:00am: Wall Street set for a mixed start The main Wall Street indices are expected to open mostly lower on Tuesday except for the narrowly-based Dow Jones 30-share index. The Dow Jones Industrial Average is tipped to edge 19 points higher to 23,132 but the more broadly-based S&P 500 is seen giving up 4 points at 4,189 while the tech-heavy Nasdaq 100 is expected to slide 20 points to 13,759. Drugs giant Pfizer Inc (NYSE:PFE), which unlike its Anglo-Swedish counterpart AstraZeneca PLC (LON:AZN) is not providing its COVID vaccine at cost, has lifted earnings guidance on the back of better-than-expected take-up of its vaccine. DuPont de Nemours Inc (NYSE:DD), the speciality materials, chemicals and agricultural products conglomerate, also lifted its full-year outlook after its first-quarter sales and earnings beat the markets expectations. Today will see the release of US factory orders and the US trade balance. Factory orders for March are expected to have risen 1.3% in March after falling 0.8%, while the trade deficit is expected to widen to US$74.3bn from Februarys US$71.1bn. Four things to watch for on Tuesday: Earnings reports are due today from a number of major firms including telecoms giant T-Mobile US Inc (NASDAQ:TMUS), video game publisher Activision Blizzard Inc (NASDAQ:ATVI) and oil & gas explorer ConocoPhillips (NYSE:COP) Shares in diagnostics firm Precipio Inc (NASDAQ:PRPO) are also in focus after the firm launched its rapid COVID-19 antibody test on Amazon overnight Pharmacy chain CVS Health Corp (NYSE:CVS) may get a look in after it upgraded its outlook and beat expectations with its latest earnings Crypto markets may also come to the fore after meme-inspired crypto Dogecoin surged in value following its listing on trading platform eToro


marketwatch
19:49 Wed 5
NwsGlbl
Biden administration backs waiving IP protections for COVID vaccines
U.S. Trade Representative Katherine Tai said in a tweet on Wednesday that the U.S. supports the waiver of intellectual-property protections on COVID-19 vaccines to 'help end the pandemic,' adding that American officials will 'actively participate' in World Trade Organization negotiations to achieve that. The White House has been under pressure from lawmakers at home and governments abroad to join an effort to waive patent rules for the vaccines so that poorer countries can begin to produce their own generic versions of the shots to vaccinate their populations. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.


marketwatch
10:25 Wed 5
Mrkts
Hilton shares slide 2.2% premarket as earnings fall short of estimates amid COVID shutdowns
Hilton Worldwide Holdings Inc. shares slid 2.2% in premarket trade Wednesday, after the hotel chain's earnings fell short of estimates, as the coronavirus pandemic continued to weigh on demand in January and February. Hilton swung to a loss of $108 million, or 39 cents a share, in the quarter, after income of $18 million, or 6 cents a share, in the year-earlier period. Excluding special items, the company had adjusted per-share earnings of 2 cents, below the 7 cents FactSet consensus. Revenue tumbled to $874 million from $1.920 billion, missing the $1.085 billion FactSet consensus. Revenue per available room fell 38.4% on a currency-neutral basis. 'While rising COVID-19 cases and tightened travel restrictions, particularly across Europe and our Asia Pacific region, weighed on demand in January and February, we saw meaningful improvement in March and April,' Chief Executive Christopher J. Nassetta said in a statement. 'We expect this positive momentum to continue as vaccines are more widely distributed and our customers feel safe traveling again.' The operations of about 275 properties, mostly in the U.S. and Europe, were suspended for some time during the first quarter, compared with about 730 properties in the year-earlier period. Shares have gained 15.3% in the year to date, while the S&P 500 has gained 10.9%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.


marketwatch
10:13 Mon 3
TrdId
Tilray says shares will start trading on Toronto Stock Exchange from May 5 after Aphria merger approved
Canadian cannabis company Tilray Inc. said Monday its shares will continue to trade on Nasdaq under the ticker symbol 'TLRY' after its merger with fellow Canadian cannabis company Aphria Inc. which shareholders approved on Friday, and will start to trade on the Toronto Stock Exchange under the same ticker from May 5. The companies are expecting the new combined company, the world's biggest cannabis company measured by revenue, to generate pretax cost-saving synergies of $81 million with 18 months of closing. Irwin D Simon, currently Aphria's CEO and chairman, will lead the new Tilray, with Tilray's current CEO joining the board. Tilray's U.S.-listed shares were up 1.3% premarket, and have gained 122% in the year to date, while the Cannabis ETF has gained 47% and the S&P 500 has gained 11%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
TLRY
Healt
marketwatch
11:22 Tue 4
NwsGlbl
Lilly to donate experimental COVID-19 treatment Olumiant to India
Shares of Eli Lilly & Co. gained 0.1% in premarket trading on Tuesday after the company said it will donate 400,000 doses of Olumiant, its rheumatoid arthritis drug that is being tested as a COVID-19 treatment for the severely ill in the U.S., to the Indian government. Lilly also said it will provide royalty-free licensing agreements to drug makers there to begin manufacturing the drug. Indian regulators on Monday authorized Olumiant as a treatment for severely ill COVID-19 patients as India's COVID-19 crisis continues to worsen. Lilly's stock is up 10.1% for the year, while the broader S&P 500 has gained 11.6%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
LLY
Healt
@ecb
08:15 Mon 3
TrdId
The rapid recovery in activity and trade is the main driver of the recent surge in shipping costs. This demand is a https://t.co/bRAbCTIc3o
-


abc net au
09:51 Mon 3
Nws
Pat Cummins in isolation as IPL teammates test positive for COVID-19
Pat Cummins is forced into isolation in Indiaand faces daily COVID tests after two of his Kolkata Knight Riders teammates test positive for COVID, leading to the postponement of an IPL game.
CMI
Indus
marketwatch
12:11 Wed 5
Nws
: Pfizers next play: A vaccine maker and pandemic partner to governments
Pfizer Inc.s COVID-19 vaccine is on track to generate a whopping $26 billion in sales this year, making it the drug makers top-selling drug and forging a new path into infectious diseases for the legacy drug maker.


indiatoday intoday in
10:09 Wed 5
TrdId
India is nowhere close to herd immunity, say experts as Covid graph soars
India is nowhere close to herd immunity, say experts as Covid graph soars


prnewswire:443
11:30 Tue 4
Nws
FluroTest Prepares to Detect SARS-CoV-2 Variants of Concern with High-Throughput COVID-19 Testing Platform
CALGARY, AB, May 4, 2021 /PRNewswire/ - FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and subsidiary FluroTest Diagnostics Systems ('FluroTest' or The Company), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to announce...


abcnews
09:33 Tue 4
Nws
UK-India trade deal includes COVID vaccine investment
Britain has announced 1 billion pounds ($1.4 billions) of new trade and investment with India, including a deal with the Serum Institute of India to aid in the development of vaccines to combat COVID-19 and other diseases


marketwatch
12:28 Tue 4
Moderna to boost COVID-19 vaccine production at Massachusetts site by 50%
Shares of Moderna Inc. were down 0.3% in premarket trading on Tuesday after the company said it will double the size of its manufacturing space at its facility in Norwood, Mass., essentially allowing for a 50% increase in the production of its COVID-19 vaccine there. Moderna now aims to produce between 800 million and 1 billion doses of its COVID-19 vaccine in 2021 and up to 3 billion doses in 2022. It also said its other products, all currently in development, can be produced at that site. 'We believe that this investment and expansion at our technology center will allow us to continue to optimize our mRNA products as we explore new pharmaceutical delivery forms such as prefilled syringes and lyophilized products,' Moderna CEO Stphane Bancel said in a news release. Moderna's stock has rallied 78.0% since the start of the year, while the broader S&P 500 is up 11.6%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
MRNA
Healt
proactiveinvestors co uk
08:01 Tue 4
Nws
Braveheart Group says Paraytec test data to be shown to potential partners
The test should be able to identify new variants of COVID-19 that might emerge believes Paraytec


reddit
17:33 Tue 4
A question about the mechanics of a short squeeze
Hi all I am trying to understand how does a short squeeze work, in particular when a person shorts a stock but can't cover it when the stock prices goes up instead of going down. I still have a gap in my understanding and I thought you maybe able to help fill it. I try to explain here: Let's suppose we have: Person 1 Person 2 Person 3 Marker Maker And 10 shares of a given stock. Initially we have: Who? Shares Person 1 0 Person 2 0 Person 3 0 Market Maker 10 Then let's say Person 1 , and Person 2 buy 1 share each: Who? Shares Person 1 1 Person 2 1 Person 3 0 Market Maker 8 Then Person 3 borrows 8 shares from the MM with the intention of shorting it: Who? Shares Person 1 1 Person 2 1 Person 3 8 'Market Maker 0 Person 3 then sells those shares to Person 1 and Person 2 at the market price (4 shares to each): Who? Shares Person 1 5 Person 2 5 Person 3 0 Market Maker 0 Let's pretend that after sometime Person 3 realizes that the share price will not go down and he gives up and decides to buy back the shares and return it to the Market Maker. Irrespective of initial prices, borrow fees, etc. Let's say Person 1 and Person 2 only sell their shares for a certain price: Who? Price Person 1 $420 Person 2 $69 Let's say Person 3 only has $5 in his bank account. Does that mean, that the Market Maker liquidates Person 3 , takes his $5, and then is obligated to buy the shares at the prices set by Person 1 , Person 2 , with two $420 shares of Person 1 remaining in his possession? submitted by /u/OxCoff33Bab3 [link] [comments]


abcnews
09:30 Wed 5
Nws
WTO mulling intellectual property waivers for vaccines
Ambassadors from World Trade Organization countries are set to discuss trade rules protecting the technological know-how behind COVID-19 vaccines


fool
10:05 Tue 4
TrdId
Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug
The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir.
LGND
Healt
news google au
19:28 Sun 2
Nws
US to launch trade talks on COVID-19 vaccine distribution - PBS NewsHour
US to launch trade talks on COVID-19 vaccine distribution    PBS NewsHour Officials say Illinois approaching 10M COVID-19 vaccines    WGN TV Chicago Qatar's COVID-19 fight gives hope as cases fall    The Peninsula Qatar WhatsApp chatbot MyGov Corona Helpdesk now lets you find nearest COVID-19 vaccination centre: How to use, other details    The Financial Express Sanders: Waiving COVID-19 vaccine patents both practical and 'moral' responsibility for U.S.    The Week View Full coverage on Google News


news google au
09:51 Mon 3
NwsGlbl
Pat Cummins in isolation as IPL teammates test positive for COVID-19, Kolkata Knight Riders' game postponed - ABC News
Pat Cummins in isolation as IPL teammates test positive for COVID-19, Kolkata Knight Riders' game postponed    ABC News Pat Cummins' IPL team in isolation after players fall ill    Wide World of Sports Community leaders slam charter flight request to bring IPL stars home    Sydney Morning Herald CA urges donations to fight India's COVID-19 crisis    cricket.com.au Pat Cummins in isolation after IPL teammates test positive for Covid-19    The Guardian View Full coverage on Google News
CMI
Indus
marketwatch
10:12 Mon 3
Nws
Moderna to supply 500 million COVID-19 vaccine doses on behalf of COVAX
Moderna Inc. announced Monday an agreement with the Vaccine Alliance, Gave, to supply up to 500 million doses of its COVID-19 vaccine on behalf of the COVAX Facility. The agreement covers the 92 Gavi COVAX Advance Market Commitment for low- and middle-income countries. Moderna's stock rose 2.3% in premarket trading. As part of the agreement, the first 34 million doses will be delivered in the fourth quarter of 2021. Also as part of the agreement, Gavi will retain the option to acquire an additional 466 million doses in 2022. 'We recognize that many countries have limited resources to access COVID-19 vaccines,' said Moderna Chief Executive Stphane Bancel. 'We support COVAX's mission to ensure broad, affordable and equitable access to COVID-19 vaccines and we remain committed to doing everything that we can to ending this ongoing pandemic with our mRNA COVID-19 vaccine.' Moderna's stock has run up 71.2% year to date, while the S&P 500 has advanced 11.3%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
MRNA
Healt
@AP
10:48 Wed 5
Nws
RT @AP_Europe: World Trade Organization ambassadors are discussing trade rules protecting the technological know-how behind COVID-19 vaccin
-


marketwatch
12:13 Mon 3
Nws
: How Fortnite maker Epic Games will try to prove Apple is operating App Store as an illegal monopoly
Epic Games Inc., the maker of 'Fortnite,' has drawn a clear battle line as it prepares for a monumental court battle against Apple Inc.: It claims the iPhone maker abuses its control of the App Store for anticompetitive purposes.
AAPL
Techn